Several other equities research analysts also recently issued reports on the company. Cantor Fitzgerald reiterated an overweight rating on shares of BioCryst Pharmaceuticals in a report on Monday, May 9th. Royal Bank of Canada lowered their target price on shares of BioCryst Pharmaceuticals from $16.00 to $14.00 and set a sector perform rating for the company in a report on Tuesday, April 12th. Piper Sandler reduced their price objective on shares of BioCryst Pharmaceuticals from $24.00 to $19.00 in a research report on Thursday, May 5th. StockNews.com cut shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday, May 12th. Finally, Evercore ISI decreased their price target on BioCryst Pharmaceuticals from $25.00 to $15.00 in a research report on Friday, April 8th. Eight analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $17.78.
BioCryst Pharmaceuticals Stock Up 2.3 %
Shares of BCRX opened at $14.05 on Friday. The business’s fifty day moving average is $10.79 and its 200 day moving average is $12.78. BioCryst Pharmaceuticals has a 12-month low of $7.61 and a 12-month high of $19.99. The stock has a market cap of $2.61 billion, a P/E ratio of -12.22 and a beta of 2.20.
Hedge Funds Weigh In On BioCryst Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Pictet Asset Management SA lifted its stake in shares of BioCryst Pharmaceuticals by 42,150.4% during the 4th quarter. Pictet Asset Management SA now owns 5,055,264 shares of the biotechnology company’s stock valued at $70,015,000 after buying an additional 5,043,299 shares in the last quarter. RP Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $43,000,000. Vanguard Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 40.3% in the first quarter. Vanguard Group Inc. now owns 13,207,040 shares of the biotechnology company’s stock worth $214,746,000 after acquiring an additional 3,794,135 shares during the period. Victory Capital Management Inc. grew its position in shares of BioCryst Pharmaceuticals by 705.3% in the first quarter. Victory Capital Management Inc. now owns 3,553,521 shares of the biotechnology company’s stock valued at $57,538,000 after purchasing an additional 3,112,255 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of BioCryst Pharmaceuticals by 4,385.7% in the second quarter. Assenagon Asset Management S.A. now owns 3,177,871 shares of the biotechnology company’s stock valued at $33,622,000 after purchasing an additional 3,107,027 shares in the last quarter. Institutional investors own 63.86% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
- Get a free copy of the StockNews.com research report on BioCryst Pharmaceuticals (BCRX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.